Q32 Bio: Oppenheimer slashes price target on mixed trial results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Rescue work underway after quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Q32 Bio Inc. (QTTB) PT Lowered to $20 at Oppenheimer
December 11, 2024 6:37 AM ESTOppenheimer analyst Jay Olson lowered the price target on Q32 Bio Inc. (NASDAQ: QTTB) to $20.00 (from $80.00) while maintaining a Outperform rating.
The analyst comments "QTTB reported negative AD but positive AA results along with an update on clinical development plans for bempikibart. While... More
